{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T02:20:03Z","timestamp":1794277203883,"version":"4.9.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03456-1","type":"journal-article","created":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T06:45:07Z","timestamp":1749797107000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Overcoming acquired immunotherapy resistance in non-small cell lung cancer using ginsenoside Rb1-loaded, peptide-enhanced exosome delivery systems"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiangyuan","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanghesi","family":"Wuyun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,13]]},"reference":[{"key":"3456_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1308525","author":"CG Ferreira","year":"2023","unstructured":"Ferreira CG, Reis MX, Veloso GGV. Editorial: molecular genetic testing and emerging targeted therapies for non-small cell lung cancer. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1308525.","journal-title":"Front Oncol"},{"issue":"2","key":"3456_CR2","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1080\/21655979.2021.2011639","volume":"13","author":"Y Wang","year":"2022","unstructured":"Wang Y, Li X, Wang H, Zhang G. CircCAMSAP1 promotes non-small cell lung cancer proliferation and inhibits cell apoptosis by sponging miR-1182 and regulating BIRC5. Bioengineered. 2022;13(2):2428\u201339. https:\/\/doi.org\/10.1080\/21655979.2021.2011639.","journal-title":"Bioengineered"},{"issue":"6","key":"3456_CR3","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3390\/medicina59061085","volume":"59","author":"HY Ahn","year":"2023","unstructured":"Ahn HY, Lee CH, Lee MK, et al. BRAF V600E mutation of non-small cell lung cancer in Korean patients. Medicina. 2023;59(6):1085. https:\/\/doi.org\/10.3390\/medicina59061085.","journal-title":"Medicina"},{"key":"3456_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215816","volume":"545","author":"W Zhao","year":"2022","unstructured":"Zhao W, Jin L, Chen P, Li D, Gao W, Dong G. Colorectal cancer immunotherapy\u2014recent progress and future directions. Cancer Lett. 2022;545: 215816. https:\/\/doi.org\/10.1016\/j.canlet.2022.215816.","journal-title":"Cancer Lett"},{"issue":"10","key":"3456_CR5","doi-asserted-by":"publisher","first-page":"358","DOI":"10.21037\/atm-22-4444","volume":"11","author":"MSC Li","year":"2023","unstructured":"Li MSC, Mok KKS, Mok TSK. Developments in targeted therapy and immunotherapy\u2014how non-small cell lung cancer management will change in the next decade: a narrative review. Ann Transl Med. 2023;11(10):358\u2013358. https:\/\/doi.org\/10.21037\/atm-22-4444.","journal-title":"Ann Transl Med"},{"key":"3456_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.945102","author":"Q Guo","year":"2022","unstructured":"Guo Q, Liu L, Chen Z, et al. Current treatments for non-small cell lung cancer. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.945102.","journal-title":"Front Oncol"},{"issue":"3","key":"3456_CR7","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/cells11030320","volume":"11","author":"S Tang","year":"2022","unstructured":"Tang S, Qin C, Hu H, et al. Immune checkpoint inhibitors in non-small cell lung cancer: progress, challenges, and prospects. Cells. 2022;11(3):320. https:\/\/doi.org\/10.3390\/cells11030320.","journal-title":"Cells"},{"issue":"3","key":"3456_CR8","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/02184923231151503","volume":"31","author":"V Erdo\u011fu","year":"2023","unstructured":"Erdo\u011fu V, \u00c7\u0131tak N, Sezen CB, et al. Survival impact of unexpected N2 in stage IIIB\/N2 non-small cell lung cancer patients. Asian Cardiovasc Thorac Ann. 2023;31(3):238\u201343. https:\/\/doi.org\/10.1177\/02184923231151503.","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"3456_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01740-y","author":"A Lahiri","year":"2023","unstructured":"Lahiri A, Maji A, Potdar PD, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer. 2023. https:\/\/doi.org\/10.1186\/s12943-023-01740-y.","journal-title":"Mol Cancer"},{"issue":"10","key":"3456_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1002\/cac2.12359","volume":"42","author":"P Chen","year":"2022","unstructured":"Chen P, Liu Y, Wen Y, Zhou C. Non-small cell lung cancer in China. Cancer Commun. 2022;42(10):937\u201370. https:\/\/doi.org\/10.1002\/cac2.12359.","journal-title":"Cancer Commun"},{"issue":"2","key":"3456_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/cancers16020335","volume":"16","author":"DM Patel","year":"2024","unstructured":"Patel DM, Mateen R, Qaddour N, et al. A comprehensive review of immunotherapy clinical trials for metastatic urothelial carcinoma: immune checkpoint inhibitors alone or in combination, novel antibodies, cellular therapies, and vaccines. Cancers. 2024;16(2):335. https:\/\/doi.org\/10.3390\/cancers16020335.","journal-title":"Cancers"},{"key":"3456_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-27156-4_5","author":"MT Tamanna","year":"2023","unstructured":"Tamanna MT, Egbune C. Traditional treatment approaches and role of immunotherapy in lung malignancy and mesothelioma. Cancer Treat Res. 2023. https:\/\/doi.org\/10.1007\/978-3-031-27156-4_5.","journal-title":"Cancer Treat Res"},{"issue":"2","key":"3456_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/jto.0000000000000074","volume":"9","author":"S Champiat","year":"2014","unstructured":"Champiat S, Ileana E, Giaccone G, et al. Incorporating immune-checkpoint inhibitors into systemic therapy of NSCLC. J Thorac Oncol. 2014;9(2):144\u201353. https:\/\/doi.org\/10.1097\/jto.0000000000000074.","journal-title":"J Thorac Oncol"},{"issue":"1","key":"3456_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/bcp.15504","volume":"89","author":"G Tang","year":"2022","unstructured":"Tang G, Liu J, Qi L, Li Y. The evolving role of checkpoint inhibitors in the treatment of urothelial carcinoma. Brit J Clin Pharma. 2022;89(1):93\u2013113. https:\/\/doi.org\/10.1111\/bcp.15504.","journal-title":"Brit J Clin Pharma"},{"key":"3456_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-023-00836-7","author":"J Liu","year":"2024","unstructured":"Liu J, Jiang Y, Chen L, Qian Z, Zhang Y. Associations between HIFs and tumor immune checkpoints: mechanism and therapy. Discov Onc. 2024. https:\/\/doi.org\/10.1007\/s12672-023-00836-7.","journal-title":"Discov Onc."},{"key":"3456_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","author":"R Rui","year":"2023","unstructured":"Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1212476.","journal-title":"Front Immunol"},{"key":"3456_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1255611","author":"F Yasinjan","year":"2023","unstructured":"Yasinjan F, Xing Y, Geng H, et al. Immunotherapy: a promising approach for glioma treatment. Front Immunol. 2023. https:\/\/doi.org\/10.3389\/fimmu.2023.1255611.","journal-title":"Front Immunol"},{"issue":"2","key":"3456_CR18","doi-asserted-by":"publisher","first-page":"375","DOI":"10.21037\/tlcr-23-742","volume":"13","author":"X Mao","year":"2024","unstructured":"Mao X, Lee NK, Saad SE, Fong IL. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review. Transl Lung Cancer Res. 2024;13(2):375\u201397. https:\/\/doi.org\/10.21037\/tlcr-23-742.","journal-title":"Transl Lung Cancer Res"},{"issue":"19","key":"3456_CR19","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.2217\/fon-2022-0045","volume":"18","author":"JA P\u00e9rez-Fidalgo","year":"2022","unstructured":"P\u00e9rez-Fidalgo JA, Criscitiello C, Carrasco E, et al. A phase III trial of alpelisib + trastuzumab \u00b1 fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA -mutated breast cancer. Future Oncol. 2022;18(19):2339\u201349. https:\/\/doi.org\/10.2217\/fon-2022-0045.","journal-title":"Future Oncol"},{"key":"3456_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04703-5","author":"S Wang","year":"2023","unstructured":"Wang S, Cheng Z, Cui Y, et al. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K\/AKT\/mTOR signaling pathway. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04703-5.","journal-title":"J Transl Med"},{"key":"3456_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8497078","author":"L Zhang","year":"2022","unstructured":"Zhang L, Li J, Zhang L. SRSF3 restriction eases cervical cancer cell viability and metastasis via adjusting PI3K\/AKT\/mTOR signaling pathway. Contrast Media Mol Imag. 2022. https:\/\/doi.org\/10.1155\/2022\/8497078.","journal-title":"Contrast Media Mol Imag"},{"key":"3456_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2021.119995","volume":"285","author":"L Zhang","year":"2021","unstructured":"Zhang L, Zheng Y, Zeng L, et al. 3-Epipachysamine B suppresses proliferation and induces apoptosis of breast cancer cell via PI3K\/AKT\/mTOR signaling pathway. Life Sci. 2021;285: 119995. https:\/\/doi.org\/10.1016\/j.lfs.2021.119995.","journal-title":"Life Sci"},{"key":"3456_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1091147","author":"C Tong","year":"2022","unstructured":"Tong C, Wu Y, Zhang L, Yu Y. Insulin resistance, autophagy and apoptosis in patients with polycystic ovary syndrome: association with PI3K signaling pathway. Front Endocrinol. 2022. https:\/\/doi.org\/10.3389\/fendo.2022.1091147.","journal-title":"Front Endocrinol"},{"key":"3456_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01200-x","author":"Z Niu","year":"2022","unstructured":"Niu Z, Jin R, Zhang Y, Li H. Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. Sig Transduct Target Ther. 2022. https:\/\/doi.org\/10.1038\/s41392-022-01200-x.","journal-title":"Sig Transduct Target Ther."},{"issue":"7","key":"3456_CR25","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.3390\/ijms22073464","volume":"22","author":"R Mishra","year":"2021","unstructured":"Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464. https:\/\/doi.org\/10.3390\/ijms22073464.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3456_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1053\/j.semdp.2020.09.010","volume":"38","author":"D Xing","year":"2021","unstructured":"Xing D, Fadare O. Molecular events in the pathogenesis of vulvar squamous cell carcinoma. Semin Diagn Pathol. 2021;38(1):50\u201361. https:\/\/doi.org\/10.1053\/j.semdp.2020.09.010.","journal-title":"Semin Diagn Pathol"},{"key":"3456_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04069-8","author":"J Liu","year":"2023","unstructured":"Liu J, Duan G, Yang W, et al. Identification of transcription factors related to diabetic tubulointerstitial injury. J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04069-8.","journal-title":"J Transl Med"},{"issue":"9\u201310","key":"3456_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1089\/ten.tea.2022.0185","volume":"29","author":"D von Stade","year":"2023","unstructured":"von Stade D, Meyers M, Johnson J, et al. Exosome cell origin affects in vitro markers of tendon repair in ovine macrophages and tenocytes. Tissue Eng Part A. 2023;29(9\u201310):282\u201391. https:\/\/doi.org\/10.1089\/ten.tea.2022.0185.","journal-title":"Tissue Eng Part A"},{"issue":"8","key":"3456_CR29","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/j.cell.2023.03.010","volume":"186","author":"R Kalluri","year":"2023","unstructured":"Kalluri R, McAndrews KM. The role of extracellular vesicles in cancer. Cell. 2023;186(8):1610\u201326. https:\/\/doi.org\/10.1016\/j.cell.2023.03.010.","journal-title":"Cell"},{"key":"3456_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-021-01428-1","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021. https:\/\/doi.org\/10.1186\/s12943-021-01428-1.","journal-title":"Mol Cancer"},{"issue":"15","key":"3456_CR31","doi-asserted-by":"publisher","first-page":"6527","DOI":"10.7150\/thno.74053","volume":"12","author":"ZZ Lai","year":"2022","unstructured":"Lai ZZ, Wang Y, Zhou WJ, et al. Single-cell transcriptome profiling of the human endometrium of patients with recurrent implantation failure. Theranostics. 2022;12(15):6527\u201347. https:\/\/doi.org\/10.7150\/thno.74053.","journal-title":"Theranostics"},{"key":"3456_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104716","volume":"155","author":"H Dianat-Moghadam","year":"2020","unstructured":"Dianat-Moghadam H, Heidarifard M, Mahari A, et al. TRAIL in oncology: from recombinant TRAIL to nano- and self-targeted TRAIL-based therapies. Pharmacol Res. 2020;155: 104716. https:\/\/doi.org\/10.1016\/j.phrs.2020.104716.","journal-title":"Pharmacol Res"},{"key":"3456_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-022-00539-5","author":"Z Fang","year":"2022","unstructured":"Fang Z, Ding Y, Xue Z, Li P, Li J, Li F. Roles of exosomes as drug delivery systems in cancer immunotherapy: a mini-review. Discov Onc. 2022. https:\/\/doi.org\/10.1007\/s12672-022-00539-5.","journal-title":"Discov Onc."},{"issue":"4","key":"3456_CR34","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/1567201819666220613150814","volume":"21","author":"ZY Guo","year":"2024","unstructured":"Guo ZY, Tang Y, Cheng YC. Exosomes as targeted delivery drug system: advances in exosome loading, surface functionalization and potential for clinical application. Curr Drug Deliv. 2024;21(4):473\u201387. https:\/\/doi.org\/10.2174\/1567201819666220613150814.","journal-title":"Curr Drug Deliv"},{"key":"3456_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117401","volume":"246","author":"S Zhang","year":"2020","unstructured":"Zhang S, Jiang L, Hu H, et al. Pretreatment of exosomes derived from hUCMSCs with TNF-\u03b1 ameliorates acute liver failure by inhibiting the activation of NLRP3 in macrophage. Life Sci. 2020;246: 117401. https:\/\/doi.org\/10.1016\/j.lfs.2020.117401.","journal-title":"Life Sci"},{"issue":"9","key":"3456_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005151","volume":"10","author":"H Ni","year":"2022","unstructured":"Ni H, Zhang H, Li L, et al. T cell-intrinsic STING signaling promotes regulatory T cell induction and immunosuppression by upregulating FOXP3 transcription in cervical cancer. J Immunother Cancer. 2022;10(9): e005151. https:\/\/doi.org\/10.1136\/jitc-2022-005151.","journal-title":"J Immunother Cancer"},{"issue":"5","key":"3456_CR37","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/s41563-023-01515-2","volume":"22","author":"S Shin","year":"2023","unstructured":"Shin S, Ko H, Kim CH, et al. Curvature-sensing peptide inhibits tumour-derived exosomes for enhanced cancer immunotherapy. Nat Mater. 2023;22(5):656\u201365. https:\/\/doi.org\/10.1038\/s41563-023-01515-2.","journal-title":"Nat Mater"},{"key":"3456_CR38","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.2147\/ijn.s291285","volume":"16","author":"B Chen","year":"2021","unstructured":"Chen B, Dong X, Dong X, et al. Integration of dual targeting and dual therapeutic modules endows self-assembled nanoparticles with anti-tumor growth and metastasis functions. IJN. 2021;16:1361\u201376. https:\/\/doi.org\/10.2147\/ijn.s291285.","journal-title":"IJN"},{"issue":"3","key":"3456_CR39","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/kjm2.12469","volume":"38","author":"W Yang","year":"2021","unstructured":"Yang W, Jiang X, Zhao X, Mao P. Treatment of RB-deficient retinoblastoma with Aurora-A kinase inhibitor. Kaohsiung J Med Sci. 2021;38(3):244\u201352. https:\/\/doi.org\/10.1002\/kjm2.12469.","journal-title":"Kaohsiung J Med Sci"},{"issue":"6","key":"3456_CR40","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3390\/medicina58060722","volume":"58","author":"MA Ortega","year":"2022","unstructured":"Ortega MA, Fraile-Martinez O, Garc\u00eda-Montero C, et al. Patients with invasive lobular carcinoma show a significant increase in IRS-4 expression compared to infiltrative ductal carcinoma\u2014a histopathological study. Medicina. 2022;58(6):722. https:\/\/doi.org\/10.3390\/medicina58060722.","journal-title":"Medicina"},{"issue":"12","key":"3456_CR41","doi-asserted-by":"publisher","first-page":"928","DOI":"10.2174\/0118715206299212240304142047","volume":"24","author":"L Feng","year":"2024","unstructured":"Feng L, Liu X, Sun K, et al. Ginsenoside Rb1 inhibits the proliferation of lung cancer cells by inducing the mitochondrial-mediated apoptosis pathway. ACAMC. 2024;24(12):928\u201341. https:\/\/doi.org\/10.2174\/0118715206299212240304142047.","journal-title":"ACAMC"},{"issue":"9","key":"3456_CR42","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.2174\/1871520623666230119092735","volume":"23","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang QQ, Xu YY, et al. Ginsenoside Rb1 suppresses AOM\/DSS-induced colon carcinogenesis. ACAMC. 2023;23(9):1067\u201373. https:\/\/doi.org\/10.2174\/1871520623666230119092735.","journal-title":"ACAMC"},{"key":"3456_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.922029","author":"Y Feng","year":"2022","unstructured":"Feng Y, Ma F, Wu E, et al. Ginsenosides: allies of gastrointestinal tumor immunotherapy. Front Pharmacol. 2022. https:\/\/doi.org\/10.3389\/fphar.2022.922029.","journal-title":"Front Pharmacol"},{"issue":"7526","key":"3456_CR44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1038\/515s1a","volume":"515","author":"L Gravitz","year":"2014","unstructured":"Gravitz L, Pincock S. Sickle-cell disease. Nature. 2014;515(7526):S1\u2013S1. https:\/\/doi.org\/10.1038\/515s1a.","journal-title":"Nature"},{"key":"3456_CR45","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.phymed.2018.10.025","volume":"56","author":"G Dai","year":"2019","unstructured":"Dai G, Sun B, Gong T, Pan Z, Meng Q, Ju W. Ginsenoside Rb2 inhibits epithelial\u2013mesenchymal transition of colorectal cancer cells by suppressing TGF-\u03b2\/Smad signaling. Phytomedicine. 2019;56:126\u201335. https:\/\/doi.org\/10.1016\/j.phymed.2018.10.025.","journal-title":"Phytomedicine"},{"issue":"2","key":"3456_CR46","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/15548627.2022.2062112","volume":"19","author":"Y Xu","year":"2022","unstructured":"Xu Y, Wan W. Acetylation in the regulation of autophagy. Autophagy. 2022;19(2):379\u201387. https:\/\/doi.org\/10.1080\/15548627.2022.2062112.","journal-title":"Autophagy"},{"issue":"11","key":"3456_CR47","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","volume":"29","author":"MD Galsky","year":"2023","unstructured":"Galsky MD, Daneshmand S, Izadmehr S, et al. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial. Nat Med. 2023;29(11):2825\u201334. https:\/\/doi.org\/10.1038\/s41591-023-02568-1.","journal-title":"Nat Med"},{"key":"3456_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114870","volume":"163","author":"L Lu","year":"2023","unstructured":"Lu L, Ao H, Fu J, et al. Ginsenoside Rb1 stabilized and paclitaxel\/protopanaxadiol co-loaded nanoparticles for synergistic treatment of breast tumor. Biomed Pharmacother. 2023;163: 114870. https:\/\/doi.org\/10.1016\/j.biopha.2023.114870.","journal-title":"Biomed Pharmacother"},{"issue":"17","key":"3456_CR49","doi-asserted-by":"publisher","first-page":"5494","DOI":"10.1158\/1078-0432.ccr-08-0233","volume":"14","author":"W Yang","year":"2008","unstructured":"Yang W, Luo D, Wang S, et al. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin Cancer Res. 2008;14(17):5494\u2013502. https:\/\/doi.org\/10.1158\/1078-0432.ccr-08-0233.","journal-title":"Clin Cancer Res"},{"key":"3456_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2345940","author":"Z Dai","year":"2024","unstructured":"Dai Z, Cai R, Zeng H, Zhu H, Dou Y, Sun S. Exosome may be the next generation of promising cell-free vaccines. Hum Vacc Immunother. 2024. https:\/\/doi.org\/10.1080\/21645515.2024.2345940.","journal-title":"Hum Vacc Immunother"},{"issue":"10","key":"3456_CR51","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1007\/s13346-021-01093-3","volume":"12","author":"W Xu","year":"2021","unstructured":"Xu W, Maqbool F, Kumar V, et al. Sustained-release ketamine-loaded lipid-particulate system: in vivo assessment in mice. Drug Deliv and Transl Res. 2021;12(10):2518\u201326. https:\/\/doi.org\/10.1007\/s13346-021-01093-3.","journal-title":"Drug Deliv and Transl Res"},{"key":"3456_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105748","volume":"170","author":"R Yuan","year":"2021","unstructured":"Yuan R, Zhao W, Wang QQ, et al. Cucurbitacin B inhibits non-small cell lung cancer in vivo and in vitro by triggering TLR4\/NLRP3\/GSDMD-dependent pyroptosis. Pharmacol Res. 2021;170: 105748. https:\/\/doi.org\/10.1016\/j.phrs.2021.105748.","journal-title":"Pharmacol Res"},{"issue":"3","key":"3456_CR53","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.jvs.2004.12.030","volume":"41","author":"FE Parodi","year":"2005","unstructured":"Parodi FE, Mao D, Ennis TL, Bartoli MA, Thompson RW. Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-\u03baB. J Vasc Surg. 2005;41(3):479\u201389. https:\/\/doi.org\/10.1016\/j.jvs.2004.12.030.","journal-title":"J Vasc Surg"},{"issue":"8","key":"3456_CR54","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1158\/2326-6066.cir-21-0865","volume":"10","author":"ST Ferris","year":"2022","unstructured":"Ferris ST, Ohara RA, Ou F, et al. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol Res. 2022;10(8):920\u201331. https:\/\/doi.org\/10.1158\/2326-6066.cir-21-0865.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"3456_CR55","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1164\/rccm.201703-0660oc","volume":"197","author":"D Ajona","year":"2018","unstructured":"Ajona D, Zandueta C, Corrales L, et al. Blockade of the complement C5a\/C5aR1 axis impairs lung cancer bone metastasis by CXCL16-mediated effects. Am J Respir Crit Care Med. 2018;197(9):1164\u201376. https:\/\/doi.org\/10.1164\/rccm.201703-0660oc.","journal-title":"Am J Respir Crit Care Med"},{"key":"3456_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2019.109126","volume":"117","author":"XY Yang","year":"2019","unstructured":"Yang XY, Liao JJ, Xue WR. FMNL1 down-regulation suppresses bone metastasis through reducing TGF-\u03b21 expression in non-small cell lung cancer (NSCLC). Biomed Pharmacother. 2019;117: 109126. https:\/\/doi.org\/10.1016\/j.biopha.2019.109126.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"3456_CR57","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/0008-5472.can-15-3142","volume":"77","author":"X Wang","year":"2017","unstructured":"Wang X, Schoenhals JE, Li A, et al. Suppression of type I IFN signaling in tumors mediates resistance to anti-PD-1 treatment that can be overcome by radiotherapy. Can Res. 2017;77(4):839\u201350. https:\/\/doi.org\/10.1158\/0008-5472.can-15-3142.","journal-title":"Can Res"},{"issue":"22","key":"3456_CR58","doi-asserted-by":"publisher","first-page":"5735","DOI":"10.1158\/1078-0432.ccr-17-3279","volume":"24","author":"S Niknam","year":"2018","unstructured":"Niknam S, Barsoumian HB, Schoenhals JE, et al. Radiation followed by OX40 stimulation drives local and abscopal antitumor effects in an anti\u2013PD1-resistant lung tumor model. Clin Cancer Res. 2018;24(22):5735\u201343. https:\/\/doi.org\/10.1158\/1078-0432.ccr-17-3279.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3456_CR59","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000289","volume":"8","author":"D Chen","year":"2020","unstructured":"Chen D, Barsoumian HB, Fischer G, et al. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020;8(1): e000289. https:\/\/doi.org\/10.1136\/jitc-2019-000289.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"3456_CR60","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.2217\/fon-2021-0862","volume":"18","author":"Y Chen","year":"2022","unstructured":"Chen Y, Chen Z, Chen R, et al. Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer. Future Oncol. 2022;18(14):1757\u201375. https:\/\/doi.org\/10.2217\/fon-2021-0862.","journal-title":"Future Oncol"},{"issue":"4","key":"3456_CR61","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.7150\/thno.43895","volume":"11","author":"L Jiang","year":"2021","unstructured":"Jiang L, Yin X, Chen YH, et al. Proteomic analysis reveals ginsenoside Rb1 attenuates myocardial ischemia\/reperfusion injury through inhibiting ROS production from mitochondrial complex I. Theranostics. 2021;11(4):1703\u201320. https:\/\/doi.org\/10.7150\/thno.43895.","journal-title":"Theranostics"},{"key":"3456_CR62","doi-asserted-by":"publisher","first-page":"4087","DOI":"10.2147\/ijn.s298252","volume":"16","author":"G Jiang","year":"2021","unstructured":"Jiang G, Wang X, Zhou Y, et al. TMTP1-modified, tumor microenvironment responsive nanoparticles co-deliver cisplatin and paclitaxel prodrugs for effective cervical cancer therapy. IJN. 2021;16:4087\u2013104. https:\/\/doi.org\/10.2147\/ijn.s298252.","journal-title":"IJN"},{"key":"3456_CR63","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-023-01281-3","author":"L Shi","year":"2023","unstructured":"Shi L, Li B, Zhang Y, et al. Exosomal lncRNA Mir100hg derived from cancer stem cells enhance glycolysis and promote metastasis of lung adenocarcinoma through mircroRNA-15a-5p\/31\u20135p. Cell Commun Signal. 2023. https:\/\/doi.org\/10.1186\/s12964-023-01281-3.","journal-title":"Cell Commun Signal"},{"key":"3456_CR64","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02717-x","author":"J Yang","year":"2023","unstructured":"Yang J, Teng Y. Harnessing cancer stem cell-derived exosomes to improve cancer therapy. J Exp Clin Cancer Res. 2023. https:\/\/doi.org\/10.1186\/s13046-023-02717-x.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"3456_CR65","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.annonc.2019.11.006","volume":"31","author":"F Mosele","year":"2020","unstructured":"Mosele F, Stefanovska B, Lusque A, et al. Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer. Ann Oncol. 2020;31(3):377\u201386. https:\/\/doi.org\/10.1016\/j.annonc.2019.11.006.","journal-title":"Ann Oncol"},{"issue":"5","key":"3456_CR66","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jtho.2020.01.027","volume":"15","author":"P Jamme","year":"2020","unstructured":"Jamme P, Fernandes M, Copin MC, et al. Alterations in the PI3K pathway drive resistance to MET inhibitors in NSCLC harboring MET exon 14 skipping mutations. J Thorac Oncol. 2020;15(5):741\u201351. https:\/\/doi.org\/10.1016\/j.jtho.2020.01.027.","journal-title":"J Thorac Oncol"},{"key":"3456_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbior.2022.100934","volume":"87","author":"NK VanLandingham","year":"2023","unstructured":"VanLandingham NK, Nazarenko A, Grandis JR, Johnson DE. The mutational profiles and corresponding therapeutic implications of PI3K mutations in cancer. Adv Biol Regul. 2023;87: 100934. https:\/\/doi.org\/10.1016\/j.jbior.2022.100934.","journal-title":"Adv Biol Regul"},{"issue":"7","key":"3456_CR68","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s12272-023-01454-1","volume":"46","author":"H Jang","year":"2023","unstructured":"Jang H, Ojha U, Jeong JH, Park KG, Lee SY, Lee YM. Myriocin suppresses tumor growth by modulating macrophage polarization and function through the PI3K\/Akt\/mTOR pathway. Arch Pharm Res. 2023;46(7):629\u201345. https:\/\/doi.org\/10.1007\/s12272-023-01454-1.","journal-title":"Arch Pharm Res"},{"issue":"2","key":"3456_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00005-017-0480-8","volume":"66","author":"K Sawa-Wejksza","year":"2017","unstructured":"Sawa-Wejksza K, Kandefer-Szersze\u0144 M. Tumor-associated macrophages as target for antitumor therapy. Arch Immunol Ther Exp. 2017;66(2):97\u2013111. https:\/\/doi.org\/10.1007\/s00005-017-0480-8.","journal-title":"Arch Immunol Ther Exp"},{"issue":"4","key":"3456_CR70","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/j.jtcvs.2019.10.070","volume":"159","author":"AL Titan","year":"2020","unstructured":"Titan AL, He H, Lui N, et al. The influence of hormone replacement therapy on lung cancer incidence and mortality. J Thorac Cardiovasc Surg. 2020;159(4):1546-1556.e4. https:\/\/doi.org\/10.1016\/j.jtcvs.2019.10.070.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"3456_CR71","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a037895","volume":"12","author":"T Cascone","year":"2021","unstructured":"Cascone T, Fradette J, Pradhan M, Gibbons DL. Tumor immunology and immunotherapy of non-small-cell lung cancer. Cold Spring Harb Perspect Med. 2021;12(5): a037895. https:\/\/doi.org\/10.1101\/cshperspect.a037895.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"3456_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.783236","author":"R Xing","year":"2021","unstructured":"Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.783236.","journal-title":"Front Immunol"},{"key":"3456_CR73","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/btt.s295406","volume":"15","author":"M Massafra","year":"2021","unstructured":"Massafra M, Passalacqua MI, Gebbia V, et al. Immunotherapeutic advances for NSCLC. Biol Target Ther. 2021;15:399\u2013417. https:\/\/doi.org\/10.2147\/btt.s295406.","journal-title":"Biol Target Ther"},{"issue":"8","key":"3456_CR74","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27(8):1345\u201356. https:\/\/doi.org\/10.1038\/s41591-021-01450-2.","journal-title":"Nat Med"},{"issue":"9","key":"3456_CR75","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","volume":"32","author":"M Reck","year":"2021","unstructured":"Reck M, Carbone DP, Garassino M, Barlesi F. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021;32(9):1101\u201310. https:\/\/doi.org\/10.1016\/j.annonc.2021.06.001.","journal-title":"Ann Oncol"},{"issue":"20","key":"3456_CR76","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.3390\/cells11203200","volume":"11","author":"H Guo","year":"2022","unstructured":"Guo H, Zhang J, Qin C, et al. Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives. Cells. 2022;11(20):3200. https:\/\/doi.org\/10.3390\/cells11203200.","journal-title":"Cells"},{"key":"3456_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01260-z","author":"L Horvath","year":"2020","unstructured":"Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC)-novel approaches and future outlook. Mol Cancer. 2020. https:\/\/doi.org\/10.1186\/s12943-020-01260-z.","journal-title":"Mol Cancer"},{"issue":"43","key":"3456_CR78","doi-asserted-by":"publisher","first-page":"17561","DOI":"10.1073\/pnas.1215397109","volume":"109","author":"Y Huang","year":"2012","unstructured":"Huang Y, Yuan J, Righi E, et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci USA. 2012;109(43):17561\u20136. https:\/\/doi.org\/10.1073\/pnas.1215397109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3456_CR79","doi-asserted-by":"publisher","first-page":"e450s","DOI":"10.6061\/clinics\/2018\/e450s","volume":"73","author":"RR da Cunha Colombo Bonadio","year":"2018","unstructured":"da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, del Diz M PE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics. 2018;73:e450s. https:\/\/doi.org\/10.6061\/clinics\/2018\/e450s.","journal-title":"Clinics"},{"issue":"2","key":"3456_CR80","doi-asserted-by":"publisher","first-page":"498","DOI":"10.7150\/thno.37745","volume":"10","author":"L Miao","year":"2020","unstructured":"Miao L, Qi J, Zhao Q, et al. Targeting the STING pathway in tumor-associated macrophages regulates innate immune sensing of gastric cancer cells. Theranostics. 2020;10(2):498\u2013515. https:\/\/doi.org\/10.7150\/thno.37745.","journal-title":"Theranostics"},{"issue":"1","key":"3456_CR81","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/biomedicines12010092","volume":"12","author":"M Xia","year":"2024","unstructured":"Xia M, Tong S, Gao L. Identification of MDK as a hypoxia- and epithelial-mesenchymal transition-related gene biomarker of glioblastoma based on a novel risk model and in vitro experiments. Biomedicines. 2024;12(1):92. https:\/\/doi.org\/10.3390\/biomedicines12010092.","journal-title":"Biomedicines"},{"issue":"4","key":"3456_CR82","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1039\/d1tb02481g","volume":"10","author":"N Alifu","year":"2022","unstructured":"Alifu N, Ma R, Zhu L, et al. A novel TMTP1-modified theranostic nanoplatform for targeted in vivo NIR-II fluorescence imaging-guided chemotherapy for cervical cancer. J Mater Chem B. 2022;10(4):506\u201317. https:\/\/doi.org\/10.1039\/d1tb02481g.","journal-title":"J Mater Chem B"},{"key":"3456_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113935","volume":"227","author":"L Wang","year":"2022","unstructured":"Wang L, Zhang D, Li J, et al. A novel ICG-labeled cyclic TMTP1 peptide dimer for sensitive tumor imaging and enhanced photothermal therapy in vivo. Eur J Med Chem. 2022;227: 113935. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113935.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"3456_CR84","doi-asserted-by":"publisher","first-page":"4241","DOI":"10.1021\/acsnano.3c09491","volume":"18","author":"A Bahreyni","year":"2024","unstructured":"Bahreyni A, Mohamud Y, Ashraf Nouhegar S, Zhang J, Luo H. Synergistic viro-chemoimmunotherapy in breast cancer enabled by bioengineered immunostimulatory exosomes and dual-targeted coxsackievirus B3. ACS Nano. 2024;18(5):4241\u201355. https:\/\/doi.org\/10.1021\/acsnano.3c09491.","journal-title":"ACS Nano"},{"key":"3456_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1299384","author":"Y Song","year":"2024","unstructured":"Song Y, Song Q, Hu D, et al. The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy. Front Oncol. 2024. https:\/\/doi.org\/10.3389\/fonc.2023.1299384.","journal-title":"Front Oncol"},{"key":"3456_CR86","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-04061-z","author":"Q Li","year":"2024","unstructured":"Li Q, He G, Yu Y, Li X, Peng X, Yang L. Exosome crosstalk between cancer stem cells and tumor microenvironment: cancer progression and therapeutic strategies. Stem Cell Res Ther. 2024. https:\/\/doi.org\/10.1186\/s13287-024-04061-z.","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"3456_CR87","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/s1875-5364(23)60400-5","volume":"21","author":"Z Dong","year":"2023","unstructured":"Dong Z, Wang H, Wang G. Research progress on the pharmacological effects and chemical constituents of Pien Tze Huang and its potential Q-markers. Chin J Nat Med. 2023;21(9):658\u201369. https:\/\/doi.org\/10.1016\/s1875-5364(23)60400-5.","journal-title":"Chin J Nat Med"},{"key":"3456_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154843","volume":"115","author":"L Hu","year":"2023","unstructured":"Hu L, Luo J, Wen G, et al. Identification of the active compounds in the Yi-Fei-San-Jie formula using a comprehensive strategy based on cell extraction\/UPLC-MS\/MS, network pharmacology, and molecular biology techniques. Phytomedicine. 2023;115: 154843. https:\/\/doi.org\/10.1016\/j.phymed.2023.154843.","journal-title":"Phytomedicine"},{"key":"3456_CR89","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1280792","author":"G Ling","year":"2024","unstructured":"Ling G, Zhang M, Chen C, et al. Progress of ginsenoside Rb1 in neurological disorders. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1280792.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3456_CR90","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/atm-22-5751","volume":"11","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Bai J, Li X, et al. Biosynthesis and pharmacokinetics of Panax notoginseng enteric-coated soft capsules. Ann Transl Med. 2023;11(2):51\u201351. https:\/\/doi.org\/10.21037\/atm-22-5751.","journal-title":"Ann Transl Med"},{"key":"3456_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155657","volume":"148","author":"ZL Tang","year":"2021","unstructured":"Tang ZL, Zhang K, Lv SC, Xu GW, Zhang JF, Jia HY. LncRNA MEG3 suppresses PI3K\/AKT\/mTOR signalling pathway to enhance autophagy and inhibit inflammation in TNF-\u03b1-treated keratinocytes and psoriatic mice. Cytokine. 2021;148: 155657. https:\/\/doi.org\/10.1016\/j.cyto.2021.155657.","journal-title":"Cytokine"},{"key":"3456_CR92","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1941077","volume":"2022","author":"M Li","year":"2022","unstructured":"Li M, Zhang W, Wang Y, et al. DDTC suppresses ovarian cancer development via the PI3K\/AKT\/mTOR signaling pathway. Dis Markers. 2022;2022:1\u201311. https:\/\/doi.org\/10.1155\/2022\/1941077.","journal-title":"Dis Markers"},{"key":"3456_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.154644","volume":"110","author":"R Li","year":"2023","unstructured":"Li R, Zheng Y, Zhang J, Zhou Y, Fan X. Gomisin N attenuated cerebral ischemia-reperfusion injury through inhibition of autophagy by activating the PI3K\/AKT\/mTOR pathway. Phytomedicine. 2023;110: 154644. https:\/\/doi.org\/10.1016\/j.phymed.2023.154644.","journal-title":"Phytomedicine"},{"key":"3456_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2023.112085","volume":"172","author":"J Peng","year":"2023","unstructured":"Peng J, Xiao X, Li S, et al. Aspirin alleviates pulmonary fibrosis through PI3K\/AKT\/mTOR-mediated autophagy pathway. Exp Gerontol. 2023;172: 112085. https:\/\/doi.org\/10.1016\/j.exger.2023.112085.","journal-title":"Exp Gerontol"},{"issue":"20","key":"3456_CR95","doi-asserted-by":"publisher","first-page":"5723","DOI":"10.1158\/0008-5472.can-13-2347","volume":"74","author":"KH Parker","year":"2014","unstructured":"Parker KH, Sinha P, Horn LA, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Can Res. 2014;74(20):5723\u201333. https:\/\/doi.org\/10.1158\/0008-5472.can-13-2347.","journal-title":"Can Res"},{"issue":"1\u20132","key":"3456_CR96","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/s0165-5728(02)00170-4","volume":"130","author":"S Columba-Cabezas","year":"2002","unstructured":"Columba-Cabezas S, Serafini B, Ambrosini E, et al. Induction of macrophage-derived chemokine\/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol. 2002;130(1\u20132):10\u201321. https:\/\/doi.org\/10.1016\/s0165-5728(02)00170-4.","journal-title":"J Neuroimmunol"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03456-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03456-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03456-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T06:45:07Z","timestamp":1749797107000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03456-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":96,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3456"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03456-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]},"assertion":[{"value":"16 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All clinical aspects of this study were approved by the Ethics Committee of Harbin Medical University Cancer Hospital. Informed consent was obtained from all participants prior to their inclusion in the study. The animal experiments in this study were approved by the Animal Ethics Committee of Harbin Medical University Cancer Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all participants prior to their inclusion in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"443"}}